InflaRx N.V.
IFRXNasdaq
$1.86
↓ -2.9%Jul 17 close · end-of-day
Price
1Y↑ +118.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
InflaRx N.V. discovers and develops inhibitors using C5a technology. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases.
- CEO
- Niels C. Riedemann
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Website
- inflarx.de
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
May 31, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.